Pharma News

HPCI Exhibition & Conference 2024 was held on 18 and 19 January, 2024 at Jio World Convention Centre, BKC, Mumbai. It was organised by ExpoNova Exhibitions & Conferences (India) Pvt. Ltd. It is the only event in India focused on raw materials and techniques for the formulation of cosmetic and cleaning products. It is indeed a place where industry meets, discovers new ingredient and technology, learns about various innovation. Companies from all over India as well as overseas participated and there was something for everyone.

Sanofi and Inhibrx, Inc. a publicly traded clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, have entered into a definitive agreement under which Sanofi has agreed to acquire Inhibrx following the spin-off of non-INBRX-101 assets into New Inhibrx. INBRX-101 is a human recombinant protein that holds the promise of allowing Alpha-1 Antitrypsin Deficiency (AATD) patients to achieve normalization of serum AAT levels with less frequent (monthly vs. weekly) dosing.

Restricting calories is known to improve health and increase lifespan, but much of how it does so remains a mystery, especially in regard to how it protects the brain. Buck scientists have uncovered a role for a gene called OXR1 that is necessary for the lifespan extension seen with dietary restriction and is essential for healthy brain aging.

Sun Pharm and Taro Pharmaceutical Industries Ltd.  announced that they have entered into a definitive merger agreement in which Sun Pharma, Taro’s controlling shareholder, has agreed to acquire all of the outstanding ordinary shares of Taro other than the shares already held by Sun Pharma or its affiliates for USD 43.00 per share in cash without interest.

Sun Pharma and Bayer announced that both companies have signed an agreement to market and distribute a second brand of Finerenone in India. Finerenone, a patented medicine is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease associated with type 2 diabetes mellitus.

Mutations, which occur continuously in every cell of our bodies, are a key contributor to cancer, ageing, and neurodegeneration. While exposure to mutagenic chemicals, or mistakes in cellular processes during DNA replication contribute to these mutations, the exact distribution and patterns of these changes across human chromosomes have remained a mystery until now.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

Researchers at Tohoku University have discovered a new approach for treating lymph node metastasis. Anticancer drugs are administered directly into the LNs under ultrasound guidance (Lymphatic Drug Delivery System or LDDS) to target sentinel lymph nodes (LNs) and generate antitumor effects locally, preventing distant metastasis. This approach not only improves the anticancer effect but also reduces the nasty side effects commonly associated with systemic chemotherapy.

A new study suggests once developed, having a universal vaccine in advance of the next coronavirus epidemic/pandemic can save up to 7 million hospitalizations and 2 million deaths even when it is the only intervention being implemented and its efficacy is as low as 10%.